Iguratimod - FUJIFILM Toyama Chemical
Alternative Names: Careram; Kolbet; T-614Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Toyama Chemical
- Developer Eisai Co Ltd; FUJIFILM Toyama Chemical
- Class Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Benzopyrans; Chromones; Small molecules; Sulfonamides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; Cytokine inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Rheumatoid arthritis
Most Recent Events
- 01 Oct 2018 Taisho Toyama Pharmaceutical returns marketing rights to FUJIFILM Toyama Chemical
- 01 Dec 2015 The Japanese Ministry of Health, Labour and Welfare lifts the All-case surveillance condition required for approval of iguratimod for Rheumatoid arthritis in Japan
- 01 Dec 2015 Interim adverse events and efficacy data from a post-marketing study in Rheumatoid arthritis released by Eisai and Toyama Chemical